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Unlike hemodialysis (HD), peritoneal dialysis (PD) is a continuous therapy
and does not induce myocardial stunning. However, since the death risk in HD
and PD patients is similar we tested the hypothesis that low serum potassium
levels contribute more to the high cardiac risk seen with PD resulting in
cardiac risk equivalent to that seen with HD in patients treated in DaVita
facilities between 7/1/2001 through 06/30/2006 in the United States (PD,
10,468; HD, 111,651). PD patients were signiﬁcantly more likely to have
serum potassium o4 meq/L (adjusted odds ratio, 3.30 (3.05, 3.56)) than HD
patients and there was a U-shaped relationship between time-averaged
serum potassium and all-cause and cardiovascular mortality (adjusted
hazards ratio for all-cause mortality, potassium o3.5 meq/L, 1.51 (1.29,
1.76); Z5.5 meq/L, 1.52 (1.32, 1.75)). However, a higher risk for infection-
related mortality was seen only with low serum potassium. The population-
attributable risks for all-cause mortality for serum potassium o4.0 and
Z5.5 meq/L were 3.6% and 1.9% respectively in PD-treated patients; the
corresponding risks in HD patients were 0.8% and 1.5% respectively. Hence,
we can conclude that abnormalities in serum potassium – particularly low
levels contribute disproportionately to the high death risk both cardiac and
non-cardiac in PD patients compared to those treated with HD. Whether
aggressive correction of abnormalities in serum potassium levels will reduce
death risk is presently not known but seems prudent to pursue.http://dx.doi.org/10.1016/j.krcp.2012.04.546223
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Recent studies have shown that brain-derived neurotrophic factor
(BDNF) is associated with neurotoxic, inﬂammatory and nutritional status .
The pulpose of this study is to investigate the changes in plasma BDNF
concentration that were induced by chronic uremic condition. Using an
enzyme-linked immunosorbent assay (ELISA), we measured peripheral
BDNF levels in pre-hemodialysis (pre-HD), peritoneal dialysis (PD) patients
and in a control group. The plasma BDNF concentrations of pre-HD, PD
patients were signiﬁcantly higher compared with those of controls (856.3
7 879.1, 1167.9 7 647.5 versus 403.1 7 288.9 pg/ml, respectively). The
plasma BDNF in dialysis patients was positively correlated with high-
sensitivity C reactive protein (hs-CRP) and with serum albumin negatively.Plasma BDNF hs-CRP Albuminr p r pPre-HD 0.321 0.025 -0.298 0.021
PD 0.414 0.070 -0.527 0.008
Pre-HD þ PD 0.446 0.001 -0.453 0.001In conclusion, BDNF might plays some role in the neurotoxicity of uremia
and associated with inﬂammation and malnutrition in dialysis patients.
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Background: Patients who are on CAPD (Continuous Ambulatory Peritoneal
Dialysis) show higher serum LDL cholesterol and Triglyceride compared to
